KR20220161395A - 중간엽 줄기 세포-유래된 암 세포 및 중간엽 줄기 세포 연관된 질환을 표적화하는 이뮤노테라노스틱 작용제 - Google Patents

중간엽 줄기 세포-유래된 암 세포 및 중간엽 줄기 세포 연관된 질환을 표적화하는 이뮤노테라노스틱 작용제 Download PDF

Info

Publication number
KR20220161395A
KR20220161395A KR1020227037264A KR20227037264A KR20220161395A KR 20220161395 A KR20220161395 A KR 20220161395A KR 1020227037264 A KR1020227037264 A KR 1020227037264A KR 20227037264 A KR20227037264 A KR 20227037264A KR 20220161395 A KR20220161395 A KR 20220161395A
Authority
KR
South Korea
Prior art keywords
binding moiety
tumor
disease
lrrc15
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227037264A
Other languages
English (en)
Korean (ko)
Inventor
한스 데이빗 얼머트
노버트 피카우스
리췬 마오
로벝 디. 다므와조
로?? 디. 다므와조
클레어 스토리
Original Assignee
더 리젠츠 오브 더 유니버시티 오브 캘리포니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 filed Critical 더 리젠츠 오브 더 유니버시티 오브 캘리포니아
Publication of KR20220161395A publication Critical patent/KR20220161395A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020227037264A 2020-04-01 2021-03-31 중간엽 줄기 세포-유래된 암 세포 및 중간엽 줄기 세포 연관된 질환을 표적화하는 이뮤노테라노스틱 작용제 Pending KR20220161395A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063003598P 2020-04-01 2020-04-01
US63/003,598 2020-04-01
PCT/US2021/025054 WO2021202642A2 (en) 2020-04-01 2021-03-31 Immunotheranostic agent targeting mesenchymal stem cell-derived cancer cells and mesenchymal stem cell associated disease

Publications (1)

Publication Number Publication Date
KR20220161395A true KR20220161395A (ko) 2022-12-06

Family

ID=77929889

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227037264A Pending KR20220161395A (ko) 2020-04-01 2021-03-31 중간엽 줄기 세포-유래된 암 세포 및 중간엽 줄기 세포 연관된 질환을 표적화하는 이뮤노테라노스틱 작용제

Country Status (9)

Country Link
US (1) US20230133775A1 (https=)
EP (1) EP4125991A4 (https=)
JP (1) JP2023520392A (https=)
KR (1) KR20220161395A (https=)
CN (1) CN115379848A (https=)
AU (1) AU2021246485A1 (https=)
BR (1) BR112022019758A2 (https=)
CA (1) CA3174263A1 (https=)
WO (1) WO2021202642A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025264059A1 (ko) * 2024-06-20 2025-12-26 주식회사 에디스바이오텍 Lrrc15에 특이적으로 결합하는 항체 및 이의 용도

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115975036B (zh) * 2022-08-18 2023-06-09 北京诺赛国际医学研究院 包含干细胞的药物组合物及其治疗癌症的用途
WO2024081729A2 (en) * 2022-10-12 2024-04-18 Mythic Therapeutics, Inc. Lrrc-15-binding protein constructs and uses thereof
TW202434310A (zh) * 2023-01-27 2024-09-01 日商第一三共股份有限公司 抗lrrc15抗體
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025160129A1 (en) * 2024-01-23 2025-07-31 The Regents Of The University Of California Methods of use of agents targeting mesenchymal stem cell- derived tumors and tumor associated cells
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9862770B2 (en) * 2005-10-19 2018-01-09 Ibc Pharmaceuticals, Inc. Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
AR090549A1 (es) * 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
SG10201900002QA (en) * 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
JP2016056165A (ja) * 2014-08-12 2016-04-21 学校法人藤田学園 抗α６β４インテグリン抗体を利用したがん又は腫瘍の診断又は治療のための抗体製剤及び抗体キット
AU2016365114A1 (en) * 2015-11-30 2018-05-17 Abbvie Biotherapeutics Inc. Anti-huLRRC15 antibody drug conjugates and methods for their use
EP3383910A1 (en) * 2015-11-30 2018-10-10 AbbVie Inc. ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
US10221242B2 (en) * 2016-01-21 2019-03-05 Pfizer Inc. Antibodies specific for epidermal growth factor receptor variant III and their uses
WO2018083087A2 (en) * 2016-11-02 2018-05-11 Glaxosmithkline Intellectual Property (No.2) Limited Binding proteins
EP3634485A4 (en) * 2017-06-07 2021-07-21 Silverback Therapeutics, Inc. CONJUGATES OF ANTIBODIES CONTAINING IMMUNOMODULATOR COMPOUNDS AND THEIR USES
TWI823906B (zh) * 2018-03-09 2023-12-01 美商艾吉納斯公司 抗-cd73 抗體及其使用方法
US20210154188A1 (en) * 2018-04-02 2021-05-27 Silverback Therapeutics, Inc. Alk5 inhibitors, conjugates, and uses thereof
CN112041337B (zh) * 2018-04-16 2025-01-07 日本医事物理股份有限公司 修饰抗体、及放射性金属标记抗体

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025264059A1 (ko) * 2024-06-20 2025-12-26 주식회사 에디스바이오텍 Lrrc15에 특이적으로 결합하는 항체 및 이의 용도

Also Published As

Publication number Publication date
EP4125991A2 (en) 2023-02-08
WO2021202642A2 (en) 2021-10-07
CA3174263A1 (en) 2021-10-07
JP2023520392A (ja) 2023-05-17
US20230133775A1 (en) 2023-05-04
WO2021202642A3 (en) 2021-11-11
AU2021246485A1 (en) 2022-11-17
BR112022019758A2 (pt) 2023-01-31
EP4125991A4 (en) 2025-02-26
CN115379848A (zh) 2022-11-22

Similar Documents

Publication Publication Date Title
KR20220161395A (ko) 중간엽 줄기 세포-유래된 암 세포 및 중간엽 줄기 세포 연관된 질환을 표적화하는 이뮤노테라노스틱 작용제
US12383637B2 (en) Therapeutic agents and uses thereof
US10646599B2 (en) Method for upregulating antigen expression
HK1256497A1 (en) Combination therapy comprising anti-cd20 antibody and the radiolabeled hh1 monoclonal antibody
EP3765523A1 (en) Bispecific binding agents and uses thereof
US20240216554A1 (en) Radioimmunoconjugates directed to nkg2d ligands for the treatment of cancer
KR20250140611A (ko) 교모세포종의 치료 방법
CA2723323A1 (en) Use of a radioactively labelled molecule specifically binding to ed-b fibronectin in a method of treatment of hodgkin lymphoma
WO2025160129A1 (en) Methods of use of agents targeting mesenchymal stem cell- derived tumors and tumor associated cells
De Santis Imaging macrophage response to radiotherapy via direct and indirect cell labelling using 89 Zr-PET in the murine 4T1-Balb/c breast cancer model
Kondo HER2-targeted Theranostic Radioimmunoconjugates for SPECT Imaging and α-particle Radioimmunotherapy of HER2-positive Breast Cancer
KR20250147080A (ko) 방사성동위원소가 표지된 항-her2 항체-킬레이터 접합체, 이를 포함하는 약학적 조성물 및 이의 제조방법
RYAN Bevacizumab radioimmunotherapy (RIT) with accelerated blood clearance using the avidin chase
Abozeid Imaging and Radio-immunotherapy of pancreatic cancer
RIT Session 4: Cancer–III
MOROZ PRECLINICAL TESTING OF NEW MODALITIES FOR PET VISUALIZATION AND TREATMENT OF RAS-DRIVEN CANCERS
HK1217438B (en) Combination therapy comprising rituximab and the radiolabeled hh1 monoclonal antibody

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902